Bridging the Valley of Death of therapeutics for neurodegeneration

被引：35

作者：

Finkbeiner, Steven ^{[1
,2
,3
]}

机构：

[1] Univ Calif San Francisco, Gladstone Inst Neurol Dis, Taube Koret Ctr Huntingtons Dis Res, Consortium Fronto Temporal Dementia Res, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA

来源：

NATURE MEDICINE | 2010年 / 16卷 / 11期

关键词：

NEUROIMAGING INITIATIVE PROGRESS; DRUG DEVELOPMENT;

D O I：

10.1038/nm.2222

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Neurodegenerative diseases are the sixth leading cause of death in the US. The market for disease-modifying drugs is enormous, but no drug exists. Academic scientists are increasingly pursuing the discovery and development of therapeutics. Their progress could potentially reduce the risk of failure sufficiently to warrant greater industry investment and movement of leads into clinical trials. Here we consider the many obstacles to the development of therapeutics for neurodegenerative disease within academia, with a special focus on organizational issues.

引用

页码：1227 / 1232

页数：6

共 31 条

[1] Market size in innovation: Theory and evidence from the pharmaceutical industry [J].